top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hBTLA mice
Strain Name
C57BL/6-Btlatm1(BTLA)Bcgen/Bcgen
Common Name  B-hBTLA mice
Background C57BL/6 Catalog number   110005
Related Genes 
BTLA (B and T lymphocyte associated)
NCBI Gene ID
208154

mRNA expression analysis 


from clipboard


Strain specific analysis of BTLA gene expression in WT and hBTLA mice by RT-PCR. Mouse Btla mRNA was detectable only in splenocytes of wild-type (+/+) mice. Human BTLA mRNA was detectable only in H/H, but not in +/+ mice. 

Protein expression analysis in T cells

from clipboard


Strain specific BTLA expression analysis in homozygous B-hBTLA mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hBTLA (H/H) mice stimulated with anti-CD3ε in vivo, and analyzed by flow cytometry with species-specific anti-BTLA antibody. Mouse BTLA was detectable in WT mice. Human BTLA was exclusively detectable in homozygous B-hBTLA but not WT mice.

Analysis of splenic leukocyte subpopulations in B-hBTLA mice

from clipboard

from clipboard


Analysis of splenic leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hBTLA mice (n=3, 6 weeks-old) and analyzed by flow cytometry to assess leukocyte subpopulations. (A) Representative FACS plots gated on single live CD45+ cells for further analysis. (B) Results of FACS analysis. Percentages of T, B, NK cells, monocyte/macrophages, and DC were similar in homozygous B-hBTLA mice and C57BL/6 mice, demonstrating that introduction of hBTLA in place of its mouse counterpart does not change the overall development, differentiation, or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

from clipboard


Analysis of splenic T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hBTLA mice (n=3, 6 weeks-old) and analyzed by flow cytometry for T cell subsets. (A) Representative FACS plots gated on CD3+ T cells and further analyzed. (B) Results of FACS analysis. Percentages of CD8+, CD4+, and Treg cells were similar in homozygous B-hBTLA and C57BL/6 mice, demonstrating that introduction of hBTLA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in spleen. Values are expressed as mean ± SEM.

Analysis of lymph node leukocyte subpopulations in B-hBTLA mice

from clipboard

from clipboard


Analysis of lymph node leukocyte subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hBTLA mice (n=3, 6 week-old) Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. (A) Representative FACS plots gated on single live CD45+ cells for further analysis. (B) Results of FACS analysis. Percentages of T, B and NK cells were similar in homozygous B-hBTLA mice and C57BL/6 mice, demonstrating that introduction of hBTLA in place of its mouse counterpart does not change the overall development, differentiation, or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of lymph node T cell subpopulations in B-hBTLA mice

from clipboard


Analysis of lymph node T cell subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hBTLA mice (n=3, 6 week-old) and analyzed by flow cytometry for T cell subsets. (A) Representative FACS plots gated on CD3+ T cells and further analyzed. (B) Results of FACS analysis. Percentages of CD8+, CD4+, and Treg cells were similar in homozygous B-hBTLA and C57BL/6 mice, demonstrating that introduction of hBTLA in place of its mouse counterpart does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.

T cells in B-hBTLA mice bind anti-human BTLA antibody

from clipboard


Analysis of splenocytes of B-hBTLA mice by FACS. Splenocytes were isolated from homozygous B-hBTLA mice.  Flow cytometry analysis of the splenocytes was performed to assess anti-human BTLA Ab1 binding with T cells. Single live cells were gated for CD45 population and used for further analysis as indicated here. T cell in homozygous B-hBTLA mice binds well with hBTLA Ab1 (in house) vs isotype control. 

In vivo efficacy of anti-human BTLA antibodies

from clipboard


Antitumor activity of anti-human BTLA antibodies in B-hBTLA mice. (A) Anti-human BTLA antibodies inhibited MC38 tumor growth in B-hBTLA mice. Murine colon cancer hHVEM MC38 cells were subcutaneously implanted into homozygous B-hBTLA mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with two anti-human BTLA antibodies with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human BTLA antibodies were efficacious in controlling tumor growth in B-hBTLA mice, demonstrating that the B-hBTLA mice provide a powerful preclinical model for in vivo evaluation of anti-human BTLA antibodies. Values are expressed as mean ± SEM. (All antibodies were made in house)

from clipboard


Antitumor activity of anti-human BTLA antibodies in B-hBTLA mice. (A) Anti-human BTLA antibodies inhibited MC38 tumor growth in B-hBTLA mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hBTLA mice (female, 6-7 week-old, n=5). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with two anti-human BTLA antibodies with doses and schedules indicated in panel A.  (B) Body weight changes during treatment. As shown in panel A, anti-human BTLA antibodies were efficacious in controlling tumor growth in B-hBTLA mice, demonstrating that the B-hBTLA mice provide a powerful preclinical model for in vivo evaluation of anti-human BTLA antibodies. Values are expressed as mean ± SEM. (All antibodies were made in house)